The current gold standard to prevent allograft rejection for maintenance immunosuppression
in kidney transplantation currently consists in glucocorticoids, an antiproliferative agent and …

The immune response to an allograft activates lymphocytes with the capacity to cause
rejection. Activation of CD4+ CD25+ Foxp3+ T regulatory cells (Treg) can down-regulate …

Immune checkpoint receptors are key players in regulating the immune response. They are
responsible for both generating an immune response sufficient to kill invading pathogens …

Regulatory T cells (Tregs) play a critical role in maintaining self-tolerance and in containing
allo-immune responses in the context of transplantation. Recent advances yielded the …

Belatacept is the first costimulatory blockade agent clinically approved for transplant
immunosuppression. While more than ten years of study have demonstrated that belatacept …

Purpose: In this review, the authors summarized the latest developments in costimulatory
blockade to prevent rejection after solid organ transplantation (SOT) and discussed …

Belatacept may be an alternative to calcineurin inhibitors and may contribute to improved
long term metabolic and allograft outcomes in kidney transplant recipients. Careful selection …

Clinical outcome prediction is important for stratified therapeutics. Machine learning (ML)
and deep learning (DL) methods facilitate therapeutic response prediction from …

Background. Maintenance immunosuppression with belatacept following kidney
transplantation results in improved long-term graft function as compared with calcineurin …

JSM receives research support from One Lambda/ThermoFisher, is a member of the
scientific advisory board for Qihan biotech, and has a family member who is employed by …